Safety and Efficacy of the Early Introduction of Everolimus (Certican) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Trial Profile

Safety and Efficacy of the Early Introduction of Everolimus (Certican) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2015 New trial record
    • 30 Jun 2014 Primary endpoint of a composite variable of the incidence of efficacy failure including biopsy-proven acute rejection, graft loss, death, or loss to follow-up until 12 months after transplantation has not been met, according to results published in the Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top